Reposted by Sara R. Fagerlie, PhD, CHCP
We not only need to treat infections in T-cell redirecting therapy recipients, but also identify high-risk patients, their risk timing, & employ risk-adapt approaches, Paula Rodriguez-Otero, MD, PhD, said. #IMS26